ACRO Biomedical Co., Ltd. (6748) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ACRO Biomedical Co., Ltd. (6748) has a cash flow conversion efficiency ratio of -0.052x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-30.47 Million) by net assets (NT$581.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ACRO Biomedical Co., Ltd. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how ACRO Biomedical Co., Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ACRO Biomedical Co., Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ACRO Biomedical Co., Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eastern Water Resources Development and Management Public Company Limited
BK:EASTW
|
0.033x |
|
Naturhouse Health SA
MC:NTH
|
0.154x |
|
Global Dividend Growth Split Corp Class A
TO:GDV
|
0.008x |
|
Nekkar Asa
OL:NKR
|
0.120x |
|
Carmel Corp Ltd.
TA:CRML
|
0.036x |
|
Shanghai Jinjiang International Travel Co Ltd
SHG:900929
|
-0.018x |
|
Venus Remedies Limited
NSE:VENUSREM
|
0.136x |
|
Votum SA
WAR:VOT
|
0.098x |
Annual Cash Flow Conversion Efficiency for ACRO Biomedical Co., Ltd. (2020–2024)
The table below shows the annual cash flow conversion efficiency of ACRO Biomedical Co., Ltd. from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$626.28 Million | NT$-43.38 Million | -0.069x | +1.56% |
| 2023-12-31 | NT$686.08 Million | NT$-48.27 Million | -0.070x | +41.01% |
| 2022-12-31 | NT$378.61 Million | NT$-45.15 Million | -0.119x | +67.58% |
| 2021-12-31 | NT$130.02 Million | NT$-47.83 Million | -0.368x | -109.50% |
| 2020-12-31 | NT$178.41 Million | NT$-31.33 Million | -0.176x | -- |
About ACRO Biomedical Co., Ltd.
ACRO Biomedical Co., Ltd. develops medical-grade regenerative biomaterials. The company offers products in the areas of wound care, orthopedics, dentistry, ophthalmology, cosmetic micro plastic surgery, beauty and eye care, and tissue engineering and regenerative medicines. The company was founded in 2014 and is based in Kaohsiung, Taiwan.